Table 1

Clinicopathological and hypermethylation detection data from 45 bladder cancer patients

No.Age/sexpTNMaStageGradeCytologyAPCRASSF1Ap14
159/FTa0aII–III+M/UU/UM/M
472/FTa0aIII+U/UU/UM/M
877/MTa0aII+M/MM/MM/M
1368/MTa0aII+U/UM/MU/U
2272/MTa0aII+M/MM/MU/U
3978/FTa0aIIIU/UM/MU/U
4080/MTa0aIIM/MM/MU/U
4357/FTa0aIIM/MU/UU/U
5565/MTa0aIN/AM/MU/UM/U
6979/MTa0aIIU/UM/MU/U
8285/FTa0aII+M/MM/MU/U
7256/MTa0aIM/MM/MU/U
10167/MTa0aIIU/UM/MU/U
10359/MTa0aIIM/MU/UM/M
10484/MTa0aIM/UU/UM/U
10556/MTa0aIIU/UU/UM/M
4884/FT1IaIIU/UU/UM/M
666/FT1IIIU/UM/UM/M
2437/MT1IIIM/MU/UU/U
2775/MT1IIIM/MM/MU/U
3561/MT1IIII+M/MU/UU/U
3757/MT1IIII+M/MM/MU/U
5369/MT1IIIM/UM/MU/U
6376/MT1III–III+M/MM/UU/U
8556/MT1IIIM/MU/UM/U
9677/FT1IIII+U/UU/UM/M
1564/MTis0isIII+U/UM/UU/U
3472/FTis0isI+M/MU/UU/U
574/MT2IIIII+M/MU/UU/U
4443/MT2IIIIIM/MM/MM/U
2874/FT3IIIIIIN/AM/MU/UU/U
4262/MT3IIIIIIN/AM/UU/UU/U
5173/FT3IIIIIIN/AM/MU/UM/M
7171/MT3IIIIIIN/AM/MM/MU/U
9872/FT3IIIIIIN/AM/UU/UU/U
9967/MT3IIIIII+U/UM/MM/M
2970/MT3IIIIIIU/UM/MU/U
2582/MT4IIIIIIN/AM/MM/UU/U
1766/MT3N1IVIIIN/AM/MM/MU/U
4566/MT3N1IVIII+U/UM/UU/U
6667/MT3N1IVIIIN/AM/UU/UM/U
7463/MT4IVIII+U/UM/MU/U
7661/MT4IVIIIN/AM/MU/UM/M
5970/MT4N1IVIIIN/AM/MU/UU/U
7544/MT4N2IVIII+M/MU/UU/U
  • a p, pathologic stage; T, tumor size; N, node status; M, metastatic status; stage, American Joint Committee on Cancer stage grouping; grade, American Joint Committee on Cancer; cytology positive, positive and 1 suspicious case (no. 22); negative, negative or mild/rare atypia and 1 degenerated case (no. 39); N/A, not available; M/M, tumor DNA methylated/urine DNA methylated; U/U, tumor DNA unmethylated/urine DNA unmethylated; M/U, tumor DNA methylated/urine DNA unmethylated. No cases of U/M (tumor DNA unmethylated/urine DNA methylated) were identified.